Articles by Walid F. Gellad, MD, MPH

Number of Manufacturers and Generic Drug Pricing From 2005 to 2017
ByInmaculada Hernandez, PharmD, PhD ,Chester B. Good, MD, MPH,Walid F. Gellad, MD, MPH,Natasha Parekh, MD, MS,Meiqi He, MS,William H. Shrank, MD, MSHS Regardless of the number of manufacturers, generic drug prices presented double-digit average increases from 2012 to 2015.

Medicaid Prior Authorization and Opioid Medication Abuse and Overdose
ByGerald Cochran, PhD,Adam J. Gordon, MD, MPH,Walid F. Gellad, MD, MPH,Chung-Chou H. Chang, PhD,Wei-Hsuan Lo-Ciganic, PhD, MS, MSPharm,Carroline Lobo, MS,Evan Cole, PhD,Winfred Frazier, MD,Ping Enrollees in Medicaid plans employing prior authorization policies for opioid medications may have lower rates of opioid medication abuse and overdose.

Long-Term Outcomes of Analogue Insulin Compared With NPH for Patients With Type 2 Diabetes Mellitus
ByJulia C. Prentice, PhD,Paul R. Conlin, MD,Walid F. Gellad, MD, MPH,David Edelman, MD,Todd A. Lee, PharmD, PhD,Steven D. Pizer, PhD There were no significant differences in the risk of ambulatory care—sensitive condition hospitalization or mortality between patients who initiated analogue insulin compared with the neutral protamine Hagedorn.

Assessing the Chiral Switch: Approval and Use of Single-Enantiomer Drugs, 2001 to 2011
ByWalid F. Gellad, MD, MPH,Phillip Choi, BS,Margaret Mizah, PharmD,Chester B. Good, MD, MPH,Aaron S. Kesselheim, MD, JD, MPH From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor.

Medicare Part D and Potentially Inappropriate Medication Use in the Elderly
ByJulie M. Donohue, PhD,Zachary A. Marcum, PharmD, MS,Walid F. Gellad, MD, MPH,Judith R. Lave, PhD,Aiju Men, MS,Joseph T. Hanlon, PharmD, MS High-risk drug use increased slightly among seniors gaining Medicare Part D coverage; however, high-risk drugs account for a small share of total drug use.

Variation in Prescription Use and Spending for Lipid-Lowering and Diabetes Medications in the Veterans Affairs Healthcare System
ByWalid F. Gellad, MD, MPH,Chester B. Good, MD, MPH,John C. Lowe, RPh, MBA,Julie M. Donohue, PhD Substantial variation in prescription spending and use of brand-name drugs exists across the VA healthcare system, with no apparent relationship to quality of care.